Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Circassia has revealed that its ToleroMune cat allergy treatment reduced patients' symptoms in its recently concluded phase II clinical trial.
Subscribe to our email newsletter
The trail is the first to use the company’s commercial room-temperature-stable formulation and provide confirmatory proof-of-concept for the final stage of development of its cat allergy T-cell vaccine.
Circassia CEO Steve Harris said with the reduction in symptoms after just four doses in addition to tolerance levels, the company’s novel T-cell vaccine has demonstrated the potential of ToleroMune to address allergy treatment.
"Our approach contrasts sharply with traditional immunotherapies, which can require dosing over a number of years under expert supervision due to the possibility of severe and even life-threatening reactions," Harris said.
"These new clinical results, combined with our earlier successful phase II studies, scientifically validate both our ToleroMune technology and the commercial formulation we intend to progress into the final stage of development."
Circassia carried out the double-blind phase II study in Toronto, Canada, randomising 202 cat allergy patients to receive either four or eight doses of ToleroMune treatment, or placebo.
The key patient group that received four doses of the T-cell vaccine over 12 weeks, had significantly reduced levels of allergy symptoms compared with placebo. These patients experienced a 55% further improvement in their symptoms.
Circassia is currently conducting a one-year follow-up study to find the duration of the treatment effect, with results expected in the second half of 2011.